NEW YORK, April  08, 2026  (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating ADMA Biologics (NASDAQ:ADMA) (&#34;ADMA Biologics&#34; or the

ADMA

Lowey Dannenberg, P.C. is Investigating ADMA Biologics (NASDAQ: ADMA) for Potential Violations of the Federal Securities Laws and Encourages Investors with more than $50,000 in Losses to Contact the Firm

ADMA Biologics Faces Investigation for Possible Securities Violations

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>NEW YORK, April  08, 2026  (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating ADMA Biologics (NASDAQ:ADMA) (&amp;#34;ADMA Biologics&amp;#34; or the</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>ADMA Biologics is facing an investigation following allegations of channel stuffing that inflated revenue figures. The findings suggest a significant revenue decline rather than growth, putting investor trust and stock value at risk.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>ADMA Biologics is under investigation for potential securities law violations.</li><li>A research firm alleged ADMA engaged in &#039;channel stuffing&#039; to inflate sales.</li><li>Reported revenue growth may have been misleading; real growth was -3%.</li><li>Investors who lost over $50,000 are encouraged to participate in legal action.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>ADMA Biologics (ADMA)</strong>: Potential legal actions could severely impact ADMA&#039;s stock price.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This falls under Corporate Developments as it directly relates to ADMA&#039;s compliance with securities laws, which could affect its market performance and reputation.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Investigation could lead to legal liabilities for ADMA Biologics.</li><li>Allegations of misleading financials could damage investor confidence and stock price.</li><li>Pending litigation may lead to operational and financial disruptions for ADMA.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>ADMA&#039;s reported growth for 2025 was allegedly inflated from a -3% real growth.</li><li>Culper Research published the report alleging channel stuffing on March 24, 2026.</li><li>Lowey Dannenberg is investigating on behalf of affected investors.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Short ADMA Biologics, as regulatory scrutiny may pressure the stock in the near term.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="justify">NEW YORK, April  08, 2026  (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating ADMA Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ADMA">ADMA</a>) ("ADMA Biologics" or the "Company") for potential violations of the federal securities laws.</p>  <p align="justify">On March 24, 2026, Culper Research, an investigative research firm, published a report titled "ADMA Biologics Inc (ADMA): Channel Stuffing, an Undisclosed Related Party Distributor, and -3% Real Growth in 2025 vs. +20% Reported." The report revealed, among other things, that in 2025 ADMA Biologics induced one of its distributors to "stock excess ASCENIV by offering rebates and extended payment terms in order to meet order expectations." This allegedly allowed ADMA Biologics to book revenue and "report[] growth that was never there." According to Culper Research, had ADMA Biologics not engaged in this alleged channel stuffing scheme, it would have experienced revenue declines of 3% in 2025 instead of the reported 20% growth.</p>  <p align="justify">If you suffered a loss of more than $50,000 in ADMA Biologics securities, and wish to participate, or learn more about your eligibility, <a href="https://www.globenewswire.com/Tracker?data=AcOkrWKjfnJeKoOg7YJZSkys7FesNSssDxMbMYq4_gQ3YjJLJy3d7tGItwNW48K-L8kNW_2jjAtV6Darlj3I62gaiAkd2VloAJ84VZtNqkA=" rel="nofollow" target="_blank">click here</a>, or contact our attorneys Andrea Farah (<a href="https://www.globenewswire.com/Tracker?data=Jk63d8RPZcUUKJvMNUvMMBCArN0Zrq89SSZGPSa3_8-2-mrtqW4VS74W0eyW5B347YPxW-o8lL1dbQFdNDumU1XTz13d5GaovTUt30XNcqs=" rel="nofollow" target="_blank">afarah@lowey.com</a>) at (914)733-7256 or Vincent R. Cappucci Jr. (<a href="https://www.globenewswire.com/Tracker?data=KM5aWn_Kxfr_WOW_ZXumIvcwCFtcJ5Ykhg4HjmOCOaE_1AKd9zdB09tUy9jeV3dT16VQ0lrB29FvzcWC27eA6VIpKoqY19DNxku9zjnUHdo=" rel="nofollow" target="_blank">vcappucci@lowey.com</a>) at (914)733-7278.</p>  <p><strong>About Lowey Dannenberg</strong></p>  <p>Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has previously recovered billions of dollars on behalf of investors.</p>  <p><strong>Contact</strong></p>  <p>Lowey Dannenberg P.C.<br></br>44 South Broadway, Suite 1100<br></br>White Plains, NY 10601<br></br>Tel: (914) 733-7256<br></br>Email:  <a href="https://www.globenewswire.com/Tracker?data=nEWYl5hF2TEXyGa6DItVsPDkSvniyEj5NUnk1jKHFlSzAba33c36syrM9HEnxXT2KE0g9Z89gKh4v7l9N3vbLu0qIsgLAfmiMZRHJCwx2ldWDt_BTYEondLXH9_3PCUJ" rel="nofollow" target="_blank">investigations@lowey.com</a> </p>  <p><strong>SOURCE:</strong> Lowey Dannenberg</p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTY4NjM1NSM3NTI1OTMwIzIxOTQ1MzQ="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/YzkyM2JlMzEtY2NiMi00MDBkLTkyZjUtMjFlOGQ5NTViZDA4LTEyMDYwODctMjAyNi0wNC0wOC1lbg==/tiny/Lowey-Dannenberg-P-C-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/38c8d81f-4a6b-4f23-8411-e6be6a60dda1"><img src="https://ml.globenewswire.com/media/38c8d81f-4a6b-4f23-8411-e6be6a60dda1/small/ld-logo-png.png" border="0" width="150" height="50" alt="Primary Logo"></img></a></p>

ADMA Biologics is facing an investigation following allegations of channel stuffing that inflated revenue figures. The findings suggest a significant revenue decline rather than growth, putting investor trust and stock value at risk.

lowey-dannenberg-p-c-is-investigating-adma-biologics-nasdaq-adma-for-potential-violations-of-the-federal-securities-laws-and-encourages-investors-with-more-than-50-000-in-losses-to-contact-the-firm

Lowey Dannenberg, P.C. is Investigating ADMA Biologics (NASDAQ: ADMA) for Potential Violations of the Federal Securities Laws and Encourages Investors with more than $50,000 in Losses to Contact the Firm

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News